A randomized (1:1), double-blind, parallel, placebo-controlled exploratory pilot study to evaluate the safety, pharmacokinetics and efficacy of systemic (po) application of MP1032 in patients with moderate to severe chronic plaque psoriasis

Trial Profile

A randomized (1:1), double-blind, parallel, placebo-controlled exploratory pilot study to evaluate the safety, pharmacokinetics and efficacy of systemic (po) application of MP1032 in patients with moderate to severe chronic plaque psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs MP 1032 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors MetrioPharm
  • Most Recent Events

    • 20 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 14 Mar 2017 Top-line results from this study published in a MetrioPharm media release.
    • 19 Dec 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top